OPINION: The Pfizer and Merck pills will only be useful if people have access to cheap, fast and accurate testing.
Nearly two years into the pandemic, it has become starkly clear that we need better treatments for COVID-19 for people in the earlier stages of disease.
As an infectious diseases physician and scientist at the University of Virginia, I have helped care for hundreds of people with COVID-19. I’ve also helped conduct clinical trials to find new treatments. Molnupiravir and Paxlovid would fill a need that hasn’t been met by other COVID-19 drugs, which are either difficult to administer or only suitable for patients in the hospital.
Early data suggests that both molnupiravir and Paxlovid are effective new drugs that patients can take at home to prevent complications of COVID-19 – which could be particularly beneficial for those at high risk of severe disease. Once authorized, these pills will allow patients to be treated earlier in the course of infection, at the point when antiviral drugs are more effective.
Molnupiravir and Paxlovid were studied in separate clinical trials with similar designs. In both studies, the drugs were tested in outpatients with risk factors for severe COVID-19 who were at an early stage in their illness. Both studies also looked at how likely patients were to either die or be hospitalized. However, neither study has yet been peer-reviewed.
If and when these drugs get authorized in the U.S., they will probably be used for the same higher-risk patients who are eligible for monoclonal antibodies today. Monoclonal antibodies may still be used, though, for pregnant people, people on dialysis and some immune-compromised patients.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Plaintiffs' lawyers get $115 mln in fees in Pfizer EpiPen dealA federal judge on Wednesday signed off on Pfizer Inc's $345 million settlement resolving claims by consumers who say they overpaid for the emergency allergy treatment EpiPen, and awarded plaintiffs' firms including Robbins Geller Rudman & Dowd and Keller Rohrback $115 million in fees.
Baca lebih lajut »
BMO initiates Pfizer at outperform, says Covid drugs and strong pipeline will boost pharma stockNew for subscribers: BMO initiates Pfizer at outperform, says Covid drugs and strong pipeline will boost pharma stock. Check out CNBCPro today.
Baca lebih lajut »
FDA authorizes Pfizer, Moderna boosters for all adults, sending process to CDC for last stepsBREAKING: The FDA has authorized booster doses of the Pfizer-BioNTech and Moderna COVID-19 vaccines for everyone 18 and older who is already considered fully vaccinated.
Baca lebih lajut »
FDA authorizes Pfizer and Moderna boosters for all adultsBREAKING: FDA authorizes Pfizer and Moderna's Covid-19 boosters for all adults, a move that will make boosters available to everyone ages 18 and up.
Baca lebih lajut »
FDA OKs Pfizer, Moderna COVID-19 booster shot for all adultsInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Baca lebih lajut »